<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404339</url>
  </required_header>
  <id_info>
    <org_study_id>PCI-03-156</org_study_id>
    <secondary_id>CDR0000515081</secondary_id>
    <secondary_id>PCI-0507062</secondary_id>
    <nct_id>NCT00404339</nct_id>
    <nct_alias>NCT00235612</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Head and Neck Cancer</brief_title>
  <official_title>Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Ferris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the&#xD;
      body build an effective immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in&#xD;
      treating patients with head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity of intranodally injected autologous dendritic cells (DC) loaded&#xD;
           with wild-type p53 peptides with or without T-helper peptide epitope in patients with&#xD;
           squamous cell carcinoma of the head and neck.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the local and systemic immunomodulatory effects of this vaccine in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study.&#xD;
&#xD;
      Patients undergo leukapheresis. The resulting dendritic cells (DC) are pulsed with wild-type&#xD;
      (wt) p53 peptides with or without T-helper (Th) peptides. Individual autologous vaccines are&#xD;
      prepared for each patient. Patients who are HLA-A2-DR4-negative are randomized to 1 of 2&#xD;
      treatment arms (arm I or arm II). Patients who are HLA-A2-DR4-positive are assigned to arm&#xD;
      III.&#xD;
&#xD;
        -  Arm I: Patients receive autologous DC loaded with HLA-A2.1-restricted wt p53 peptides&#xD;
           only.&#xD;
&#xD;
        -  Arm II: Patients receive autologous DC loaded with HLA-A2.1-restricted wt p53 peptides&#xD;
           and Th tetanus toxoid peptide.&#xD;
&#xD;
        -  Arm III (HLA-A2-DR4-positive patients only): Patients receive autologous DC loaded with&#xD;
           HLA-A2.1-restricted wt p53 peptides and Th wt p53 peptide.&#xD;
&#xD;
      In all arms, each vaccine is administered by ultrasonography-guided inguinal intranodal&#xD;
      injection over 30 minutes on days 0, 14, and 28.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity profile and overall toxicity rates</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic response rate as measured by ELISPOT assay prevaccination and at days 14 and 18</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Biologic response rate</measure>
  </primary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mutant p53 peptide pulsed dendritic cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tetanus toxoid helper peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck&#xD;
&#xD;
               -  Resectable disease&#xD;
&#xD;
               -  Any stage allowed&#xD;
&#xD;
          -  Successfully treated with curative intent&#xD;
&#xD;
          -  Recurrent disease allowed provided the following criteria are met:&#xD;
&#xD;
               -  No evidence of disease&#xD;
&#xD;
               -  At least 6 weeks since prior antitumor therapy&#xD;
&#xD;
          -  Positive for HLA-A2.1&#xD;
&#xD;
               -  HLA-DR4 allele status known&#xD;
&#xD;
          -  Tumor tissue must be available&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Granulocyte count &gt; 2,500/mm^3&#xD;
&#xD;
          -  Lymphocyte count &gt; 700/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 0.2 mg/dL&#xD;
&#xD;
          -  Creatinine &lt; 0.2 mg/dL&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for ≥ 1 week before, during, and for&#xD;
             ≥ 2 weeks after study completion&#xD;
&#xD;
          -  No systemic infection or coagulation disorders&#xD;
&#xD;
          -  No psychiatric disturbances that would preclude obtaining informed consent or safe&#xD;
             conduct of protocol&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Hepatitis B surface antigen and hepatitis C antibody negative&#xD;
&#xD;
          -  No other active malignancies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior adjuvant radiotherapy or chemoradiotherapy&#xD;
&#xD;
               -  No time restriction for prior curative therapy&#xD;
&#xD;
          -  No concurrent pharmacological doses of steroids in any form (topical or systemic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L. Ferris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <last_update_submitted>April 14, 2016</last_update_submitted>
  <last_update_submitted_qc>April 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Robert Ferris</investigator_full_name>
    <investigator_title>UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology</investigator_title>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

